The FML (Fucose Mannose Ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar
| Autor: | Kleber Luz, Linnete V. de Medeiros, Edilma Paraguai de Souza, Elza M. Gomes, Sirley R. de Macedo, Claris B. Palatnik de Sousa, Wania Renata Santos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1996 |
| Předmět: |
Microbiology (medical)
Chagas disease Glicoconjugado Blood transfusion lcsh:Arctic medicine. Tropical medicine Kala-azar lcsh:RC955-962 Glycoconjugate medicine.medical_treatment Leishmania donovani Protozoan Proteins Antigens Protozoan Blood Donors Enzyme-Linked Immunosorbent Assay Ligands Leishmanial antigens Mice Calazar parasitic diseases Diagnosis Medicine Animals Humans Chagas Disease Amastigote Subclinical infection Fucose Visceral leishmaniasis biology Transfusão de sangue business.industry Diagnóstico Vaccination medicine.disease biology.organism_classification Prognosis Infectious Diseases Immunization Immunology Leishmaniasis Visceral Parasitology Female business Mannose Brazil |
| Zdroj: | Revista da Sociedade Brasileira de Medicina Tropical v.29 n.2 1996 Revista da Sociedade Brasileira de Medicina Tropical Sociedade Brasileira de Medicina Tropical (SBMT) instacron:SBMT Revista da Sociedade Brasileira de Medicina Tropical, Vol 29, Iss 2, Pp 153-163 (1996) Revista da Sociedade Brasileira de Medicina Tropical, Volume: 29, Issue: 2, Pages: 153-163, Published: APR 1996 |
| Popis: | The Fucose-Mannose Ligand (FML) of Leishmania donovani is a complex glycoproteic fraction. Its potential use as a tool for diagnosis of human visceral leishmaniasis was tested with human sera from Natal, Rio Grande do Norte, Brazil. The FML-ELISA test, showed 100% sensitivity and 96% specificity, identifying patients with overt kala-azar (p < 0.001, when compared to normal sera), and subjects with subclinical infection. More than 20% apparently healthy subjects with positive reaction to FML developed overt kala-azar during the following 10 months. In the screening of human blood donnors, a prevalence of 5% of sororeactive subjects was detected, attaining 17% in a single day. The GP36 glycoprotein of FHL is specifically reconized by human kala-azar sera. The immunoprotective effect of FML on experimental L. donovanii infection was tested in swiss albino mice. The protection scheemes included three weekly doses of FML, supplemented or not with saponin by the subcutaneous or intraperitoneal routes and challenge with 2x 10(7) amastigotes of Leishmania donovani. An enhancement of 80.0 % in antibody response (pO FML (Ligame de Fucose-Manose) de Leishmania donovani é uma fração glicoproteica complexa. O seu potencial no diagnóstico da leishmaniose visceral humana foi testado com soros provenientes de Natal, Rio Grande do Norte, Brasil. O teste de FML-ELISA mostrou 100% de sensibilidade e 96% de especificidade, identificando pacientes com calazar declarado (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|